Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -262.78K | -258.71K | -264.18K | -56.22K | EBIT |
-60.12T | -42.79M | -62.68M | -56.22M | -36.42M | EBITDA |
-60.12T | -35.21M | -60.07M | -55.77M | -36.07M | Net Income Common Stockholders |
-55.85T | -37.54M | -61.37M | -59.25M | -37.55M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
10.00T> | 142.82M | 174.30M | 229.79M | 77.86M | Total Assets |
10.00T> | 148.33M | 181.29M | 233.14M | 83.35M | Total Debt |
15.30M | 15.66M | 16.08M | 15.86M | 15.33M | Net Debt |
-39.22M | -127.17M | -128.34M | -213.93M | -62.53M | Total Liabilities |
33.60T | 28.53M | 30.28M | 27.40M | 23.84M | Stockholders Equity |
71.00T | 119.80M | 151.01M | 205.74M | 59.51M |
Cash Flow | Free Cash Flow | |||
-43.21T | -30.33M | -56.65M | -42.56M | -37.49M | Operating Cash Flow |
-43.21T | -30.33M | -56.64M | -42.56M | -37.49M | Investing Cash Flow |
-44.92T | 30.00M | -29.95M | -7.81K | 29.02M | Financing Cash Flow |
-171.42B | -1.27M | 1.22M | 194.50M | 41.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $5.36B | 3.88 | -42.93% | 2.87% | 17.85% | 1.45% | |
50 Neutral | $139.95M | ― | -124.10% | ― | 9.22% | 60.01% | |
49 Neutral | $183.12M | ― | -50.77% | ― | ― | -54.29% | |
39 Underperform | $111.76M | ― | -31.94% | ― | ― | 30.76% | |
39 Underperform | $127.62M | ― | -77.09% | ― | ― | -2.29% | |
37 Underperform | $162.32M | ― | -58.54% | ― | ― | -47.28% | |
35 Underperform | $253.26M | ― | -84.70% | ― | ― | 32.58% |
On April 17, 2025, Aldeyra Therapeutics announced the appointment of Chip Clark as a Class I director on its board, expanding the board to eight members. Mr. Clark, with over three decades of experience in the biopharmaceutical industry, is expected to contribute significantly to Aldeyra’s strategic direction as it advances its pipeline addressing unmet medical needs in immune-mediated and metabolic diseases.
Spark’s Take on ALDX Stock
According to Spark, TipRanks’ AI Analyst, ALDX is a Underperform.
Aldeyra Therapeutics faces significant financial challenges with no current revenue and ongoing losses. The negative trend in technical analysis and high regulatory risk from the FDA’s response letter further weigh down the stock’s outlook. Despite its strong cash reserves, the company’s sustainability depends heavily on successful product development and overcoming regulatory hurdles.
To see Spark’s full report on ALDX stock, click here.
On April 3, 2025, Aldeyra Therapeutics announced receiving a Complete Response Letter from the FDA regarding its resubmitted New Drug Application for reproxalap, intended for treating dry eye disease. The FDA highlighted the need for additional well-controlled studies due to concerns about the efficacy data and methodological issues in previous trials. Aldeyra plans to address these issues with ongoing trials and aims to resubmit the NDA by mid-2025, although this may require more resources and delay the drug’s approval and commercialization, impacting the company’s financial condition and market strategy.